[Trial prevention of vaso-occlusive crises in homozygote sickle cell anemia using piracetam].
作者信息
Sonnet J, Gini E K, Cornu G
出版信息
Ann Soc Belg Med Trop. 1985;65(1):77-84.
PMID:4004377
Abstract
摘要
相似文献
1
[Trial prevention of vaso-occlusive crises in homozygote sickle cell anemia using piracetam].[使用吡拉西坦对纯合子镰状细胞贫血进行血管闭塞性危象的试验性预防]
Ann Soc Belg Med Trop. 1985;65(1):77-84.
2
Use of piracetam improves sickle cell deformability in vitro and in vivo.使用吡拉西坦可在体外和体内改善镰状细胞的可变形性。
J Clin Pathol. 1987 Jan;40(1):99-102. doi: 10.1136/jcp.40.1.99.
3
Piracetam and acetamide in sickle-cell disease.吡拉西坦与乙酰胺治疗镰状细胞病
Lancet. 1977 Aug 20;2(8034):411.
4
Piracetam in sickle-cell anaemia.吡拉西坦治疗镰状细胞贫血
Lancet. 1976 Nov 20;2(7995):1139-40. doi: 10.1016/s0140-6736(76)91120-x.
5
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.DOVE（确定血小板抑制对血管闭塞事件的影响）试验设计：一项全球性3期双盲、随机、安慰剂对照、多中心研究，采用剂量滴定策略评估普拉格雷在镰状细胞贫血儿科患者中的疗效和安全性。
Pediatr Blood Cancer. 2016 Feb;63(2):299-305. doi: 10.1002/pbc.25771. Epub 2015 Sep 24.
6
Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease.吡拉西坦对预防镰状细胞病儿童和青少年疼痛性危象无效。
Acta Haematol. 2005;113(4):228-33. doi: 10.1159/000084675.
7
Sickle-cell disease: Two new therapeutic strategies.镰状细胞病：两种新的治疗策略。
Lancet. 1978 Sep 9;2(8089):570-1. doi: 10.1016/s0140-6736(78)92898-2.
8
Erythrocyte - endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: adverse effects reversed with piracetam.镰状细胞病、糖尿病和恶性疟疾中的红细胞 - 内皮细胞黏附：吡拉西坦可逆转不良影响。
Med Hypotheses. 1982 Feb;8(2):155-62. doi: 10.1016/0306-9877(82)90098-6.
9
[Vaso-occlusive pain crises in children with sickle cell anemia].[镰状细胞贫血患儿的血管阻塞性疼痛危象]
Soins Pediatr Pueric. 2007 Feb(234):21-6.
10
Painful crises in children with sickle cell disease are not prevented by piracetam.患有镰状细胞病的儿童的疼痛性危象不能通过吡拉西坦预防。
Acta Haematol. 2009;121(1):9-10. doi: 10.1159/000205261. Epub 2009 Feb 27.
引用本文的文献
1
Piracetam for reducing the incidence of painful sickle cell disease crises.吡拉西坦用于降低疼痛性镰状细胞病危机的发生率。
Cochrane Database Syst Rev. 2016 Feb 12;2(2):CD006111. doi: 10.1002/14651858.CD006111.pub3.
2
Use of piracetam improves sickle cell deformability in vitro and in vivo.使用吡拉西坦可在体外和体内改善镰状细胞的可变形性。
J Clin Pathol. 1987 Jan;40(1):99-102. doi: 10.1136/jcp.40.1.99.
Zotero 插件